|
|
European Urinary Incontinence Therapeutics MarketsPublished by: Frost & Sullivan Published: Jul. 11, 2007 - 73 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled European Urinary Incontinence Therapeutics Markets provides an overview of the current treatment options in the markets. The study offers a detailed analysis of the key drivers, restraints, trends and the technological advances in the markets. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: urge urinary incontinence, stress urinary incontinence and mixed urinary incontinence.This research service is available through our Pharmaceuticals and Biotechnology Growth Partnership Services program. With this program you receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Increasing Awareness of Urinary Incontinence and the Launch of Improved Products to Propel Market Growth Urinary incontinence (UI) is a condition in which the body loses control over the bladder and this leads to involuntary leaking of urine. While this can occur in both men and women, it is twice as common in women. The condition typically affects elderly individuals aged 60 and above. As it is a cause of great social embarrassment, several patients do not seek treatment for it. "Over the last three years, the European UI therapeutics markets have been highly dynamic due to the release of new improved products," notes the analyst of this research service. "The sale of these new products has grown at a very high rate and has subsequently altered the competitive landscape of the market." The main reason for the high growth rates of these products has been their improved side effect profile. With the expected launch of few more novel products in the future, the market is set to witness sustained growth. Apart from these launches, demographic changes such as an ageing population and increasing awareness will drive market growth. SUI therapeutics market will continue to face stiff competition from alternative therapies Currently, the therapeutic treatment options available in the market are basically to treat urge urinary incontinence (UUI) and are associated with certain side effects that nullify the effect of the drug (such as the incidence of dry mouth). However, the launch of new product lines with lesser side effects is likely to favourably influence the market. Other restraints that have prevented the market from growing to its real potential are the social stigma attached to the disease and the low priority given to UI by physicians. While several positive trends augur well for the overall markets, the stress urinary incontinence (SUI) therapeutics markets remain at a very nascent stage of development. The SUI therapeutic market is underdeveloped, with only one product which has been approved and the uptake of this product has been below expectations. SUI treatment market will continue to be dominated by alternative therapies. "The lack of therapeutic options for the treatment of SUI will be the biggest lacunae in the markets," explains the analyst. "Increasing the awareness level of the sole therapeutic option for SUI is crucial for the success of the product." Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||